title: Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody.
abstract: GD3, a ganglioside expressed on tumors of neuroectodermal origin such as melanoma and small-cell lung carcinoma (SCLC), is an attractive vaccine target but is poorly immunogenic. Our group has pursued several strategies designed to immunize patients against GD3 including using BEC2, an anti-idiotypic monoclonal antibody that mimics GD3. Pilot trials in melanoma and SCLC indicate that BEC2 can induce an anti-GD3 antibody response in a subset of patients and also suggests that immunization with BEC2 is associated with improved survival. A phase III trial is underway in SCLC patients to determine the effects of BEC2 on overall survival.
authors.affiliation: Clinical Immunology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. chapmanp@mskcc.org
authors.forename: Paul B
authors.initials: PB
authors.lastname: Chapman
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000276:immunology / Q000628:therapy; D051638:Ether-A-Go-Go Potassium Channels; D005732:Gangliosides / Q000037:antagonists & inhibitors* / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active / Q000379:methods* / Q000639:trends; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D009419:Nerve Tissue Proteins / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D015221:Potassium Channels / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D024642:Potassium Channels, Voltage-Gated
chemical_list: D000888:Antibodies, Anti-Idiotypic; D051638:Ether-A-Go-Go Potassium Channels; D005732:Gangliosides; C121382:KCNH4 protein, human; D009419:Nerve Tissue Proteins; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; C026226:ganglioside, GD3